Press Releases

December 6 - Nurosene Chief Science Officer Presents at Leading Drug Development Forum

December 1 - Nurosene Business Update

October 31 - Nurosene Health Inc. Announces Closing of Private Placement

October 14 - Nurosene Health Inc. Announces Closing Private Placement

August 24 - Nurosene Appoints Neurosurgeon Dr. Douglas James Cook as Chief Medical Officer

August 23 - Nurosene Appoints New Advisory Board Member Dhananja Jayalath

July 22 - Nurosene Appoints Industry Veteran Dr. Luca Pani as Chief Innovation and Regulatory Officer

July 19 - Nurosene Announces Appointment of New CFO

July 14 - Nurosene Appoints Seasoned Executive Josh Spiegel as President of Netramark

July 6 - Nurosene Announces Agreement with Denovo Biopharma LLC to Optimize Treatment-Resistant Depression Trial

June 22 - Nurosene Enters Into Agreement with Taylored Biotherapeutics to Evaluate Clinical Trial Results

June 8 - Nurosene Health Inc. Announces Closing of Private Placement

June 8 - Nurosene's Chief Scientific Officer to Present at World Orphan Drug Congress USA 2022

May 27 - Nurosene Enters Into Agreement with a Speciality Biopharma Company to Generate Insights from Clinical Trial Results

May 19 - Nurosene's Chief Scientific Officer Publishes Paper on AI and Placebo Response

View All +

Financial Reporting

Q3 2021 - Interim Financial Results

Q3 2021 - MD&A

Corporate Governance

Notice of Meeting & MIC for AGM - April 1, 2022

Proxy - AGM 2022

Code Business Conduct and Ethics

Audit Committee Charter

Nurosene

[Head Office]

1655 Dupont St. #Suite 101

Toronto, ON M6P 3S9

investors@nurosene.com

Fasken Martineau DuMoulin LLP

[Legal]

2400 - 333 Bay St.

Toronto, ON M5H 2T6

416.366.8381

MNP LLP

[Auditors]

111 Richmond St. W Suite 300

Toronto, ON M5H 2G4

416.596.1711

Odyssey Trust

[Transfer Agent]

United Kingdom Building 323

409 Granville Street

Vancouver, BC V6C 1T2

1.833.392.7716